Invion (ASX: IVX) progresses photodynamic technology for treating cancer (w/ Thian Chew)

Invion (ASX: IVX) chairman Thian Chew joins Small Caps to discuss the company's ongoing development of its next generation photodynamic therapy INV-043 for treating an array of malignancies. Initial proof-of-concept testing of the treatment has shown great promise across a range of cancers. With its success in in vivo cancer research, Invion is also looking at using INV-043 to treat viral, bacterial, fungal and parasitic conditions.